Bank of America Corp DE Sells 246,592 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Bank of America Corp DE decreased its position in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 93.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 17,010 shares of the company's stock after selling 246,592 shares during the period. Bank of America Corp DE's holdings in Kodiak Sciences were worth $169,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Ameriprise Financial Inc. raised its position in Kodiak Sciences by 26.1% during the 4th quarter. Ameriprise Financial Inc. now owns 38,624 shares of the company's stock valued at $384,000 after purchasing an additional 7,996 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $9,950,000. TCG Crossover Management LLC raised its holdings in Kodiak Sciences by 13.6% in the 4th quarter. TCG Crossover Management LLC now owns 1,145,538 shares of the company's stock worth $11,398,000 after purchasing an additional 137,380 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in Kodiak Sciences by 287.2% in the fourth quarter. Nantahala Capital Management LLC now owns 266,613 shares of the company's stock worth $2,653,000 after buying an additional 197,756 shares during the period. Finally, Northern Trust Corp boosted its position in Kodiak Sciences by 2.9% during the 4th quarter. Northern Trust Corp now owns 269,597 shares of the company's stock valued at $2,682,000 after acquiring an additional 7,678 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "neutral" rating and set a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.

Kodiak Sciences Stock Performance

Shares of KOD traded down $0.14 on Monday, hitting $3.74. 281,725 shares of the stock traded hands, compared to its average volume of 348,335. The company has a market capitalization of $197.34 million, a PE ratio of -1.02 and a beta of 2.27. The business has a 50 day simple moving average of $3.59 and a 200 day simple moving average of $5.27. Kodiak Sciences Inc. has a one year low of $1.92 and a one year high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20). On average, equities analysts expect that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.